NEW OR RETURNING USERS: SIGN IN  |   UPDATE PROFILE  |   CME/CE TRACKER    



  

Gastroenterology

On-Demand Webcast 3
                      Updated Approaches for Treating
                      Hepatitis B

 

This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Updated Approaches for Treating
Hepatitis B
On-Demand Webcast 3


Dear Colleague,

As a result of new therapies, updated guidelines, and data from recent studies, approaches to treating chronic hepatitis B virus (HBV) infection are evolving and being refined. Selection of an appropriate antiviral agent is critical for optimal suppression of HBV DNA in the short and long term and for prevention of treatment resistance. Initial selection of some previously standard antiviral therapies such as lamivudine may predispose patients to cross-resistance with other antivirals. It is now more important than ever that clinicians remain up-to-date about current thinking on the management of HBV infection.

We are excited that you have decided to join us for this CME/CE webcast, Updated Approaches for Treating Hepatitis B, which is part of the curriculum of the Advanced Certificate Program II: Management of Chronic Hepatitis B. This activity will provide the most current information about treatment of chronic infection with HBV, including 2006 and 2007 updates to treatment guidelines and the newest data and expert opinions regarding use of lamivudine, adefovir, entecavir, peginterferon, and telbivudine.

We are sure you will find these current perspectives helpful in furthering your care of patients infected with HBV.

Sincerely,

CO-CHAIR
Adrian M. Di Bisceglie, MD, FACP
Professor of Internal Medicine
Chief of Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri




Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chairs of Advanced Certificate Program II: Management of Chronic Hepatitis B, alternate to help develop content for the audioconferences. This audioconference was developed by Dr. Adrian M. Di Bisceglie and Dr. Michael W. Fried.

FACULTY
Kris V. Kowdley, MD
Professor of Medicine
Division of Gastroenterology/Hepatology
University of Washington Medical Center
Seattle, Washington
top

TARGET AUDIENCE
This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.

ACTIVITY GOAL
The goal of this CME/CE activity is to examine the latest information about treating chronic hepatitis B virus (HBV) infection, taking into account the most current guidelines, recent FDA approvals, and new data, in order to effectively suppress viral replication.

LEARNING OBJECTIVES
  • Select an appropriate antiviral agent for treating chronic HBV infection by considering current treatment guidelines and recent evidence-based data to improve patient responses.

  • Monitor HBV DNA and adjust treatment approaches based on response and development of resistance in patients with hepatitis B in order to achieve and maintain viral suppression.
top

CME INFORMATION—PHYSICIANS

Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME INFORMATION—PHYSICIAN ASSISTANTS
Projects In Knowledge will issue a certificate of participation for each course the participant completes. Please check with your organization and/or society for reciprocity.

CE INFORMATION—NURSES
This activity has been approved by the American Association of Critical-Care Nurses (AACN) for a maximum of 1.0 contact hour. Provider #00012705.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Adrian M. Di Bisceglie, MD, FACP, has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Chiron Corporation, Metabasis Therapeutics, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Bristol-Myers Squibb Company, Idenix Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.

Kris V. Kowdley, MD, is on the speakers bureau of Gilead Sciences, Inc, and Hoffmann-La Roche Inc; and is a consultant for Bristol-Myers Squibb Company and Gilead Sciences, Inc.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

This CME/CE activity will contain a discussion of the unlabeled/unapproved uses of emtricitabine, emtricitabine in combination with tenofovir, and tenofovir.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.


This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb Company.
top

1767

 

 

Program Information

Faculty
Target Audience
Activity Goal
Learning Objectives
CME Information
Disclosure Information
Technical Requirements


By clicking below, I certify that I have read the accompanying CME/CE and disclosure information and am ready to continue to this activity.

View Webcast

Release Date: March 1, 2007.

Termination Date: March 1, 2008.

Estimated Time for Completion of this Activity: 1.0 hour.

CME/CE Instructions

To obtain credit for this activity:
  1. View the entire webcast carefully.
  2. Complete/submit the posttest and evaluation.
  3. Instantly access and print out your certificate.


Recommend this page
Recommend this to a colleague


There is no fee for this activity.

This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb Company.




ABOUT US  |  CONTACT US  |  CONTRACT  |  DIRECTIONS  |  PRIVACY POLICY  |  RESOURCES
Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988